Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)

Market Cap	1.92B -26.6%
Revenue (ttm)	209.51M +49.6%
Net Income	-100.02M
EPS	-0.91
Shares Out	109.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,128,997
Open	17.49
Previous Close	17.45
Day's Range	17.44 - 17.97
52-Week Range	14.42 - 33.67
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Jiangsu CoWin Biotech

Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit; molecular raw materials; quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA sequencing, and single cells sequencing products; molecular cloning, such as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 769
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688426

Financial Performance

In 2025, Jiangsu CoWin Biotech's revenue was 193.52 million, an increase of 53.74% compared to the previous year's 125.88 million. Losses were -107.41 million, -31.68% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 4, 2026

Data Sources Report a data error